Truist analyst Jailendra Singh lowered the firm’s price target on Hims & Hers to $10 from $12 and keeps a Hold rating on the shares. Better than expected Q2 results were more than offset by investor concerns around the company’s pricing action, the analyst tells investors in a research note. Truist notes however that the management emphasized in a follow-up call that the pricing action during the quarter was more of a proactive decision as the company has not seen any meaningful change in the competitive market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HIMS:
- Hims & Hers Health Stock (NYSE:HIMS): An Opportunity to Get Your Blood Pumping
- Hims & Hers price target lowered to $10 from $11 at Piper Sandler
- Hims & Hers (NYSE:HIMS) Soars On Robust Q2 Outing
- Hims & Hers jumps 16% to $9.15 after Q2 earnings beat, guidance raise
- Hims & Hers raises FY23 revenue view to $830M-$850M from $810M-$830M